phenylbutyric acid

LU901 is an investigational controlled-release oral formulation of phenylbutyric acid (4-phenylbutyrate), a small molecule histone deacetylase (HDAC) inhibitor. Developed by Lunamed Operations AG, the drug is designed to modulate gene expression through epigenetic mechanisms, specifically by inhibiting the deacetylation of histones to promote an open chromatin state. LU901 is being evaluated in Phase 2 clinical trials in Germany for the treatment of metastatic prostate carcinoma. In these studies, it is administered as a 500 mg daily dose in addition to standard androgen deprivation therapy to assess its safety, tolerability, and potential to overcome treatment resistance in patients with disease progression.

Other names

4-phenylbutyrate4-phenylbutyric acid4-PBAphenylbutyrate